Trials / Conditions / Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8

Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8

23 registered clinical trials studyying Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 — 13 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cann NCT07441681	NRG Oncology	Phase 3
Recruiting	Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Ca NCT07195734	National Cancer Institute (NCI)	Phase 2
Recruiting	Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN281 NCT06980038	National Cancer Institute (NCI)	Phase 2
Not Yet Recruiting	Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squ NCT07156227	National Cancer Institute (NCI)	Phase 1
Recruiting	Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy f NCT06532279	NRG Oncology	Phase 2
Recruiting	Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluati NCT06914999	Emory University	EARLY_Phase 1
Withdrawn	Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carbopl NCT06084845	ECOG-ACRIN Cancer Research Group	Phase 2
Recruiting	De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA NCT05541016	Mayo Clinic	Phase 2
Recruiting	BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Mel NCT05136196	National Cancer Institute (NCI)	Phase 2
Withdrawn	A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Canc NCT05512767	Mayo Clinic	N/A
Recruiting	Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer NCT05172245	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Tr NCT04576091	National Cancer Institute (NCI)	Phase 1
Suspended	Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advan NCT05050162	NRG Oncology	Phase 2 / Phase 3
Active Not Recruiting	Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cance NCT04533750	National Cancer Institute (NCI)	Phase 1
Not Yet Recruiting	Surgery Vs Chemoradiation for Oropharyngeal Cancer- A Phase II/III Integrated Design Randomized Control Trial NCT05144100	Tata Memorial Centre	Phase 2 / Phase 3
Completed	Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer NCT04870840	M.D. Anderson Cancer Center	Phase 1
Completed	Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With NCT04541355	Hyunseok Kang, MD	Phase 2
Withdrawn	Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer NCT04140513	Ohio State University Comprehensive Cancer Center	N/A
Terminated	Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer NCT04162873	University of Utah	Phase 2
Recruiting	Oropharynx (OPX) Biomarker Trial NCT06356272	Mayo Clinic	—
Completed	Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck NCT03258554	National Cancer Institute (NCI)	Phase 2 / Phase 3
Recruiting	Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With NCT03010150	M.D. Anderson Cancer Center	—
Recruiting	Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of NCT02734537	ECOG-ACRIN Cancer Research Group	Phase 2